Side-by-side · Research reference

AOD-9604vsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed10/47 cited

BHuman-MechanisticDraft11/40 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2008

~30 minHalf-life

SQ · Abdomen · Daily fasted

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

AOD-9604

Selank

Primary target

β3-adrenergic receptor (proposed)Ng 2008

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

No GH-axis or IGF-1 feedback

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

Selank

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

150–300 mcg / dose intranasalZaderej 2014

Frequency

Once daily, fasted

2–3× per day during stress

Lower / starter dose

150 mcg / day

75 mcg / dose

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2008

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

8–12 weeks per cycle

10–14 day cycles, repeated as needed

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Morning + early afternoon preferred

Half-life

~30 min plasma

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

AOD-9604

Selank

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

—

Pregnancy / OB

Avoid

Avoid — insufficient data

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

AOD-9604

Selank

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle

29–31G, 4–8 mm insulin syringe.

Avoid co-administration with strong sedatives or other anxiolytics initially.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

Selank

— no documented stacks